Tissue diagnostics are the most important set of techniques, majorly used for diagnosis, monitoring and management of cancer. This market constitutes instruments, reagents and kits used to determine the prognosis, stage and treatment course of the disease. Tissue diagnostics is observed as one of the most important and efficient technology that captures the biological context of the disease and other critical parameters observed in patients outcome. Accessioning, gross cassette verification, tissue processing, embedding, microtomy, order entry, primary staining, advanced staining, case assembly, pathologist review and archive are the various processes of tissue diagnostics. The three major tissue diagnostics tests are Hematoxylin and Eosin (H&E), Immunohistochemistry (IHC) and In-situ hybridization (ISH). H&E is the most widely used staining medical diagnosis, used for highlighting structures in tissue for evaluation.IHC is a process of using antibodies to stain particular proteins; it greatly increases the ability to identify categories of cells and ISH is an advanced technique to identify specific DNA or RNA molecules.
Browse Full Report@ http://www.futuremarketinsights.com/reports/tissue-diagnostics-market
The major drivers of this market are increase in incidences of cancer globally, incidences forced most of the labs to improve the efficiencies to manage test volumes, increase in automation and standardization to maximize patient safety gains high patient preference.
The tissue diagnostics market can be segmented on the basis of technology as immunohistochemistry (IHC), in-situ hybridization (ISH) digital pathology & workflow and special staining. Immunochemistry is the segment which is the largest segment due to its wide applications in tissue diagnostics and the use of IHC products is increasing as companion diagnostics in personalized medicine for cancer. The tissue diagnostics market can be segmented also on the basis of diseases such as breast cancer, gastric cancer, lymphoma, prostate cancer, non-small-cell lung cancer and others. In these segments breast cancer disease segment was observed to be the largest market as is the most common form of cancer in women and is highly acquiescent for tissue diagnostics. The global tissue diagnostics market can be segmented on the basis of its end users such as hospitals, research laboratories, contract research organizations (CROs) and pharmaceutical companies.
Request Report TOC@ http://www.futuremarketinsights.com/toc/rep-gb-406
North America is the largest tissue diagnostics market globally due to increase in demand for advanced cancer diagnostics, high awareness about cancer, one of the most prevalent geographical region for breast cancer patients and high accessibility to modern diagnostic techniques for patients. The increase in demand for advanced cancer diagnostics was observed due to introduction of The Patient Protection and Affordable Care Act (PPACA) in the U.S. in March 2010 which was expected to benefit more than 30 million U.S citizens to get insurance access. Europe was observed to be the second largest market. According to World Cancer Research Fund International in year 2012, the top 4 countries observed to have highest breast cancer suffering population were Belgium, Denmark, France and The Netherlands. Asia –Pacific and Rest of the World (RoW) are expected to be the regions developing highest growth rate. Developing healthcare infrastructure, increasing awareness against cancer and various government initiatives are assisting the growth of these markets.
The major players in the tissue diagnostics market are Abbott Laboratories, Roche Diagnostics, Agilent Technologies, Thermo Fisher Scientific and Danaher Corporation. Other important players in this market are Sigma-Aldrich, Biogenex Laboratories, Cell Signaling Technology, Life Technologies and Bio SB.